On August 8, 2024, Assembly Biosciences, Inc. reported its financial results for the second quarter ended June 30, 2024. The announcement included the initiation of dosing in Phase 1a/b trials for ABI-5366, targeting recurrent genital herpes, with interim data expected in Q3 2024 and first half of 2025. Additionally, dosing began in a Phase 1b trial for ABI-4334 in chronic HBV infection patients, with interim data anticipated by the end of 2024. The company also expects to introduce two more pipeline candidates, ABI-1179 and ABI-6250, into clinical trials by year-end. Assembly Biosciences highlighted its strengthened balance sheet with equity investments totaling approximately $12.6 million, extending its cash runway into Q1 2026. The company's cash and cash equivalents stood at $109.2 million as of June 30, 2024. Revenue from collaborative research was $8.5 million for...Show More

On August 8, 2024, Assembly Biosciences, Inc. reported its financial results for the second quarter ended June 30, 2024. The announcement included the initiation of dosing in Phase 1a/b trials for ABI-5366, targeting recurrent genital herpes, with interim data expected in Q3 2024 and first half of 2025. Additionally, dosing began in a Phase 1b trial for ABI-4334 in chronic HBV infection patients, with interim data anticipated by the end of 2024. The company also expects to introduce two more pipeline candidates, ABI-1179 and ABI-6250, into clinical trials by year-end. Assembly Biosciences highlighted its strengthened balance sheet with equity investments totaling approximately $12.6 million, extending its cash runway into Q1 2026. The company's cash and cash equivalents stood at $109.2 million as of June 30, 2024. Revenue from collaborative research was $8.5 million for the quarter, attributed to the collaboration with Gilead Sciences, Inc. Research and development expenses increased to $16.3 million, while general and administrative expenses decreased to $4.5 million. The net loss for common stockholders was $11.2 million, or $1.98 per share. The company emphasized its commitment to developing therapeutics for serious viral diseases and outlined upcoming milestones for its clinical programs.